Affinity Asset Advisors, LLC

CIK 0001773195 · NEW YORK, NY · Quarter end: 2026-06-30 · Filed on: 2026-08-13 · Open the SEC source

Affinity Asset Advisors, LLC reported 113 positions worth $2.21B as of June 30, 2026 (13F filed August 13, 2026). Largest holding: ROIV (6.0%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$2.21B
2026 Q2
Positions
113
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
39.4%
Est. Net Flow (Q)
2026 Q2
10 / 113 positions shown
#SymbolCompanyTypeValue% Port.Shares1YYTD
1ROIVROIVANT SCIENCES LTDSH$132.7M6.00%3,750,000
203770N101APOGEE THERAPEUTICS INCSH$131.0M5.92%987,000
3SYRESPYRE THERAPEUTICS INCSH$113.6M5.13%1,279,134
4XENEXENON PHARMACEUTICALS INCSH$96.3M4.35%1,595,000
5ERASERASCA INCSH$96.2M4.35%5,250,000
6INSMINSMED INCSH$69.3M3.13%650,000
7PRAXPRAXIS PRECISION MEDICINES ISH$61.9M2.80%185,000
8ALKSALKERMES PLCSH$58.9M2.66%1,125,000
9ORKAORUKA THERAPEUTICS INCSH$56.2M2.54%590,000
10ANABANAPTYSBIO INCSH$55.8M2.52%826,109

The free plan shows the top 10 positions. The remaining 103 positions, the full portfolio and quarter changes unlock with Pro.

Pro Feature

This section is exclusive to Fundocap Pro. Full holdings tables, consensus trades, ownership analysis, backtests and exports unlock with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does Affinity Asset Advisors, LLC hold as of Q2 2026?

Affinity Asset Advisors, LLC reported 113 positions worth $2.21B in its Q2 2026 13F filing. Largest positions: ROIV (6.0%), APOGEE THERAPEUTICS INC (5.9%), SYRE (5.1%), XENE (4.4%) and ERAS (4.3%).

What did Affinity Asset Advisors, LLC buy in Q2 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did Affinity Asset Advisors, LLC sell in Q2 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.